Patent ID: 11970743
Assignee: DENDREON PHARMACEUTICALS LLC
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A method of treating a patient having metastatic castration-resistant prostate cancer (mCRPC), the method comprising the steps of:
(a) obtaining a biological sample from the patient, wherein the biological sample is selected from the group consisting of whole blood, peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), and tumor tissue;
(b) measuring in the biological sample an expression product level of at least two biomarkers selected from the group consisting of SYNGR3, AURKC, CHI3L2, SNTB1, ZNF268, COL1A1, LAX1, DPPA4, CDK5RAP2, KCNQ5, ZFYVE28, DNAH11, and TAP2;
(c) determining a first composite score of expression product levels of the biomarkers measured in step (b), the first composite score corresponding to a probability of overall survival in response to treatment with sipuleucel-T; and
(d) administering an immunotherapy sipuleucel-T to the patient based on the first composite score that is higher or lower than an expression threshold that is relative to a control group of subjects that do not meet the expression threshold.